Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-11-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
福安药业：公司章程（2021年11月）
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 福安药业（集团）股份有限公司, which is a detailed legal and governance document outlining the company's organizational structure, shareholder rights, board responsibilities, and procedural rules for shareholder meetings. It includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the articles, and supplementary provisions. The content is focused on governance, shareholder rights, meeting procedures, and company internal rules rather than financial performance, audit results, or announcements. This type of document fits the category of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the full governance document, not a brief announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2021-11-19 Chinese
股东大会议事规则修订对照表（2021年11月）
Governance Information Classification · 95% confidence The document is titled as a comparison table of amendments to the "Shareholders' Meeting Rules" of the company 福安药业（集团）股份有限公司. It details specific changes to the rules governing the conduct of shareholders' meetings, including who presides over meetings and voting rights. The document references relevant laws and the company's board meeting that approved the amendments, and it states that the amendments still require approval at the shareholders' meeting. This is a governance-related document focused on internal rules and procedures for shareholder meetings, not a financial report, announcement of voting results, or a proxy solicitation. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication or a certification, so RPA or RNS are not appropriate. Hence, the classification is CGR with high confidence.
2021-11-19 Chinese
关于召开2021年第三次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2021 third extraordinary general meeting of shareholders for the company 福安药业（集团）股份有限公司. It includes information about the meeting date, agenda items such as election of board members and amendments to company bylaws, voting procedures including cumulative voting, registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not the results of the vote or the meeting itself. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is not a voting results announcement (DVA) because it does not provide the outcome of the votes, nor is it a management or board change announcement (MANG) since it only proposes elections. It is also not a regulatory filing or report publication announcement as it contains substantive meeting notice content rather than a brief announcement or certification. Therefore, the best classification is AGM Information (AGM-R).
2021-11-19 Chinese
关于为全资子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for a subsidiary's bank credit application. It includes details about the guarantee, the subsidiary's financials, board and supervisory opinions, and compliance with regulatory rules. It does not contain a full financial report, audit report, or earnings release. The document is a specific announcement about financing-related guarantees, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on a financing guarantee, not a full report or regulatory filing. Therefore, the best classification is CAP.
2021-11-19 Chinese
独立董事候选人声明（朱姝）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There are no financial statements, earnings data, or report summaries. The document is not an annual report, audit report, earnings release, or any financial report. It is also not a voting result or a proxy solicitation. Instead, it is a formal declaration related to board/management information, specifically concerning the appointment or candidacy of an independent director. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5214 characters) supports it being a full declaration rather than a brief announcement.
2021-11-19 Chinese
独立董事候选人声明（熊文说）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It includes detailed statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no discussion of company performance, no voting results, no management changes, and no mention of any report publication. The document is a regulatory compliance statement related to board/management information, specifically about an independent director candidate's qualifications and declarations. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5092 characters) and content support this classification with high confidence.
2021-11-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.